Effect of Sacubitril/Valsartan in Patients with Acute Exacerbation of Chronic Heart Failure

Not Applicable

Recruiting

• Conditions: Acute Exacerbation of Heart failure

• Registration Number: JPRN-UMIN000046583
• Lead Sponsor: ippon Medical School

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-01-10
• Last Update Posted: 17 October 2023
• Study Completion: 2025-07-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients heart failure due to ST elevation myocardial infarction 2) Patients with end-stage chronic kidney disease (eGFR<30 mL/min/1.73m2) were excluded from present study. 3) Patients who satisfied the matters that requires attention in appended paper.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes to the natriuretic peptide families (BNP, NT-proBNP and ANP)

Secondary Outcome Measures

Name	Time	Method
1) serum renin, aldosterone and AngiotensinII 2) medications 3) age, gender, presence of de novo or recurrent HF, etiology of HF, past medical history (risk factors for atherosclerosis [diabetes mellitus, hypertension, and dyslipidemia], and chronic kidney disease), vital signs (systolic blood pressure [SBP] and heart rate), presence of orthopnea, arterial blood gas data, laboratory data (blood urea nitrogen, creatinine, total bilirubin, sodium, potassium, hemoglobin, BNP, C-reactive protein [CRP] 4)left ventricular ejection fraction (LVEF) on echocardiography 5)long-term prognosis (all cause death and HF event within 1 year)